Svetlana Shikanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Svetlana Shikanova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Anwar Abdelazim
Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
10 shared publications - Bakyt Karimova
Department of Obstetrics and Gynecology №1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
6 shared publications - Gulmira Zhurabekova
Department of Normal and Topographical Anatomy, Marat Ospanov, West Kazakhstan State Medical University (WKSMU), Aktobe, Kazakhstan
5 shared publications - Mohannad Abu-Faza
Department of Obstetrics and Gynecology, Ahmadi Hospital, Kuwait Oil Company (KOC), Ahmadi, Kuwait
4 shared publications - Mukhit Sarsembayev
Department of Obstetrics and Gynecology №1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
4 shared publications - Gulmira Mukhambetalyeva
Department of Obstetrics and Gynecology №1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
3 shared publications
Latest Publications
- 8 April 2021
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 3 (6) , 1344-1349
Heme-Iron Optifer Versus Intravenous Iron/Ferosac in Treatment of Iron Efficiency Anemia During Pregnancy
- 8 April 2021
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 3 (6) , 1344-1349
Heme-Iron Optifer Versus Intravenous Iron/Ferosac in Treatment of Iron Efficiency Anemia During Pregnancy
- 16 February 2021
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 3 (3) , 862-869
The Outcome of the Hospital Protocol for Prevention of Surgical Site Infection After Cesarean Deliveries
- 16 February 2021
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 3 (3) , 862-869
The Outcome of the Hospital Protocol for Prevention of Surgical Site Infection After Cesarean Deliveries
- Open Access
- 1 January 2021
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-6
Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy
OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.
- 1 January 2021
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-6
Open AccessHeme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy
OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.
- Open Access
- 21 October 2020
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 2 (12) , 2834-2839
Diagnostic Accuracy of Insulin-like Growth Factor–Binding Protein-1/alpha-Fetoprotein (AmnioQuick Duo) in Ruptured Fetal Membranes
- 21 October 2020
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 2 (12) , 2834-2839
Open AccessDiagnostic Accuracy of Insulin-like Growth Factor–Binding Protein-1/alpha-Fetoprotein (AmnioQuick Duo) in Ruptured Fetal Membranes
- Open Access
- 1 January 2020
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 59 (1) , 169
Comments on Combined Endoloop® ligation and pessary cerclage devices for delayed interval delivery: A first case report
- 1 January 2020
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 59 (1) , 169
Open AccessComments on Combined Endoloop® ligation and pessary cerclage devices for delayed interval delivery: A first case report
- 2 July 2019
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 68, 166-167
Comments on the Manuscript entitled: Laparoscopic treatment of cornual heterotopic pregnancy: A retrospective cohort study
- 2 July 2019
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 68, 166-167
Comments on the Manuscript entitled: Laparoscopic treatment of cornual heterotopic pregnancy: A retrospective cohort study
- 9 March 2019
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 69 (5) , 476-477
Comments on Manuscript: Interstitial and Cornual Ectopic Pregnancy: Conservative Surgical and Medical Management
- 9 March 2019
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 69 (5) , 476-477
Comments on Manuscript: Interstitial and Cornual Ectopic Pregnancy: Conservative Surgical and Medical Management
- 31 January 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (6) , 1747-1748
Risk factors, microbiology, and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies: letter to the editor
- 31 January 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (6) , 1747-1748
Risk factors, microbiology, and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies: letter to the editor
- 1 January 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 232, 107-108
Open cornual resection versus laparoscopic cornual resection in patients with interstitial ectopic pregnancies
- 1 January 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 232, 107-108
Open cornual resection versus laparoscopic cornual resection in patients with interstitial ectopic pregnancies
- 22 October 2018
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 298 (6) , 1231-1232
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Iron deficiency (ID) and iron deficiency anemia (IDA) in pregnancy are global health issues, affecting around 30% of women in high-resourced countries, and increasing to over 50% of women in low-resourced countries.
- 22 October 2018
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 298 (6) , 1231-1232
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Iron deficiency (ID) and iron deficiency anemia (IDA) in pregnancy are global health issues, affecting around 30% of women in high-resourced countries, and increasing to over 50% of women in low-resourced countries.